Dr. Menard has established himself as a dynamic program manager, a skilled clinical investigator, and a highly regarded mentor, trainer, and strategist. His operational experience in pre-clinical and early stage clinical development with leading bio-pharmaceutical companies provides extensive background and hands-on drug development, operations, research, and clinical experience. His knowledge of early stage drug development, from validating novel targets to preparing comprehensive IND-enabling packages and proof of concept in man, provides for excellent scientific direction for MyCROsite Pre-clinical Solutions. Starting at AstraZeneca, Dr. Menard led project teams and received accolades for his contributions toward developing the company's first candidate drug, and for doing so in record time. At MDS Pharma Services, he combined hands-on laboratory skills with exceptional capabilities in marketing, product development, and business development, to play a critical role in the growth and expansion of diverse product lines. As VP of Pharmacology he developed cohesive and collaborative global teams. He joined Algos Therapeutics to lead their transition from a business model of proprietary drug development to a mature, targeted, and grounded CRO. Dr. Menard has established and directed pharmacology toxicology and this experience has provided the confidence to help found MyCROsite Pre-clinical Solutions. Proven capabilities in budget/resource management and in hiring, training, and retaining high-performing global teams. Balancing creativity and innovation with practicality and sensibility, he approaches challenges with enthusiasm and determination and has been successful in fostering and maintaining strategic partnerships with his staff, leadership teams, and external partners. He is an exceptional component of the MyCROsite management team.

Jamie is an innovative business leader combining an acute business acumen with broad scientific excellence that has assisted over 700 biotechnology/pharmaceutical companies reach unparalleled levels of success. He is an expert in drug discovery and development who consults with biotechnology and pharmaceutical companies to advance projects to IND filing. He leverages his 20+ years of drug discovery experience and his passion for therapeutic evaluation to help researchers and companies achieve program success. In Jamie's philosophy, the introduction of new methods for drug discovery and development should allow for better medicines to be discovered in a shorter period of time. He is focused on innovative approaches to drug discovery that will provide collaborators and clients the best solutions for project success.

Andy graduated from the University of Bristol with M.Sc. in Advanced Analytical Chemistry in 1989 and Ph.D. in Analytical Chemistry in 1996. Ph.D. thesis "The High Quality Monitoring of PAHs in Potable Waters". Dr. Cooke has three years of experience in GLP bioanalysis at Huntingdon Life Sciences, joined OSI Pharmaceuticals in 1999, and from 2002 to 2012 was the head of Research DMPK at OSI Pharmaceuticals (later Astellas) in Boulder CO. During that time he managed a team of to 5 carrying out live phase and bioanalytical work in oncology drug discovery projects. Although he is not trained in hands-on animal techniques, Dr. Cooke has 11 years of experience in working closely with In-vivo Pharmacology and managing live phase work in mouse and rat models of cancer and diabetes along with supervising the optimization of dried blood spot sampling techniques allowing repeated non-terminal sampling in the mouse. In addition, he has broad experience in DMPK from high throughput drug discovery to pre-clinical and clinical trials, expertise in development of high quality bioanalytical methods, PK study design and modeling, as well as being highly familiar with managing in-vitro and in-vivo studies at multiple CROs.

Kirsten is an in vivo neuropharmacologist with a scientific background in the areas of pain and drugs of abuse. She received a Masters degree in Biological Sciences in 1999 from the University of Northern Colorado and her Ph.D. degree from The Ohio State University in Integrated Biomedical Sciences in 2009. After completing her Ph.D. she went to The Scripps Research Institute for her postdoctoral training. Her graduate and postgraduate research was completed in the laboratory of Dr. Laura Bohn, where she investigated how the regulation of opioid receptors by G protein receptor kinases (GRKs) and beta-arrestins (βarrs) can determine physiological and behavioral responses to opioids in vivo. Her work revealed that βarr2 plays an important role in mediating opiate drug responsiveness in vivo and that disrupting opioid receptor-mediated βarr2 signaling may improve opiate pain relief while subsequently attenuating the development of adverse side effects like analgesic tolerance, physical dependence, respiratory suppression and constipation. In 2012, Kirsten joined Purdue Pharma L.P. as a Senior Research Scientist in their Drug Discovery In Vivo Sciences group. There she was involved in designing, testing, and disseminating animal study results for several different pain projects that focused on developing new and improved pain therapeutics. She then joined myCROsite team as a Senior Scientist in October of 2014. Dr. Raehal is well published, having 16 peer-reviewed publications and 32 poster abstracts. She was also the recipient of an F31 Ruth Kirschstein Pre-doctoral Research Award from the National Institute on Drug Abuse and has several accolades for her graduate and postdoctoral work. Further, she is a member of a number of professional societies, including the American Society for Pharmacology and Experimental Therapeutics and the Society for Neuroscience.

Tonja graduated from Colorado State University with a Bachelor of Science Degree in Biology followed by a Master of Science Degree in Molecular Immuno-virology. Her thesis work involved creation of a novel monoclonal antibody-selected variation of the TC-83 vaccine for Venezuelan Equine Encephalitis Virus, Molecular Determinants of Venezuelan Equine Encephalitis Virus Vector Infection. Throughout her career she was involved in research at Colorado State University in Fort Collins and at the Institute for Behavioral Genetics in Boulder. She has extensive experience in both in vitro and in vivo techniques with primary focus on various behavioral testing systems and models. Specifically, Tonja has proficiency with Contextual Fear Conditioning, Morris Water Maze Task, and Nose Poke Food Training in both mice and rats. Along with the live models, she was also expected to harvest brain, plasma, and other tissues from these animals. With respect to in vitro analysis, she is proficient in PCR analysis, DNA preparation and sequencing techniques, GEL electrophoresis, cell culture, ELISA testing, immunofluorescent staining, and monoclonal antibody production. In addition to a background in research, her three-year position as Director of Client Services for an online Medical Transcription company has further developed her skills for professional and courteous customer service, excellent organization, and attention to detail.

Becky has been a Certified Veterinery Technician since 1994. She was employed at both WSU and CSU Vet Teaching Hospitals, several small private practices, a large 24-hour Vet Clinic in Alexandria VA, and OSI Pharmaceuticals in Boulder CO where she was certified as a Registered Lab Animal Technician. Over the last 8 years Becky has worked in Animal Care where she was subsequently promoted to Research Associate followed by Senior RA in DMPK/InVIvo Pharmacology. Her research work has provided experience with both rats and mice, doing all manner of injections and dosing, as well as ordering, ADME and DDI work, study organization, independently working on PK projects, and most notably, becoming an expert in sole jugular vein blood collection from rats and saphenous blood draws in mice. The field of research has afforded the opportunity to contribute to the progress of cancer treatment in hopes of finding affective treatments/cures for present and future patients.